Palatin

Banking

Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension

February 28, 2023
Photo of Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension

[ad_1] CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines…

Read More »
Banking

Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

February 15, 2023
Photo of Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

[ad_1] Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results…

Read More »
Banking

Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

February 10, 2023
Photo of Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

[ad_1] CRANBURY, N.J., Feb. 10, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal…

Read More »
Back to top button
Close